JP2022512234A5 - - Google Patents
Info
- Publication number
- JP2022512234A5 JP2022512234A5 JP2021533356A JP2021533356A JP2022512234A5 JP 2022512234 A5 JP2022512234 A5 JP 2022512234A5 JP 2021533356 A JP2021533356 A JP 2021533356A JP 2021533356 A JP2021533356 A JP 2021533356A JP 2022512234 A5 JP2022512234 A5 JP 2022512234A5
- Authority
- JP
- Japan
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024025175A JP7811315B2 (ja) | 2018-12-11 | 2024-02-22 | 補体関連疾患のための融合タンパク質構築物 |
| JP2025279839A JP2026053563A (ja) | 2018-12-11 | 2025-12-24 | 補体関連疾患のための融合タンパク質構築物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862778014P | 2018-12-11 | 2018-12-11 | |
| US62/778,014 | 2018-12-11 | ||
| PCT/US2019/065741 WO2020123662A2 (en) | 2018-12-11 | 2019-12-11 | Fusion protein constructs for complement associated disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024025175A Division JP7811315B2 (ja) | 2018-12-11 | 2024-02-22 | 補体関連疾患のための融合タンパク質構築物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022512234A JP2022512234A (ja) | 2022-02-02 |
| JP2022512234A5 true JP2022512234A5 (https=) | 2023-07-31 |
| JPWO2020123662A5 JPWO2020123662A5 (https=) | 2023-07-31 |
| JP7444886B2 JP7444886B2 (ja) | 2024-03-06 |
Family
ID=71076704
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533356A Active JP7444886B2 (ja) | 2018-12-11 | 2019-12-11 | 補体関連疾患のための融合タンパク質構築物 |
| JP2024025175A Active JP7811315B2 (ja) | 2018-12-11 | 2024-02-22 | 補体関連疾患のための融合タンパク質構築物 |
| JP2025279839A Pending JP2026053563A (ja) | 2018-12-11 | 2025-12-24 | 補体関連疾患のための融合タンパク質構築物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024025175A Active JP7811315B2 (ja) | 2018-12-11 | 2024-02-22 | 補体関連疾患のための融合タンパク質構築物 |
| JP2025279839A Pending JP2026053563A (ja) | 2018-12-11 | 2025-12-24 | 補体関連疾患のための融合タンパク質構築物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240301043A1 (https=) |
| EP (1) | EP3893916A4 (https=) |
| JP (3) | JP7444886B2 (https=) |
| KR (2) | KR102762828B1 (https=) |
| CN (1) | CN113660944A (https=) |
| AU (2) | AU2019398214C1 (https=) |
| IL (1) | IL283841A (https=) |
| MA (1) | MA54468A (https=) |
| MX (1) | MX2021006930A (https=) |
| MY (1) | MY209796A (https=) |
| PH (1) | PH12021551398A1 (https=) |
| SG (1) | SG11202106073QA (https=) |
| WO (1) | WO2020123662A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018075783A2 (en) * | 2016-10-20 | 2018-04-26 | President And Fellows Of Harvard College | In vitro and cell based assays for measuring the activity of botulinum neurotoxins |
| CA3141778A1 (en) * | 2019-06-12 | 2020-12-17 | CSL Innovation Pty Ltd | Soluble complement receptor type 1 variant conjugates and uses thereof |
| AU2021293174A1 (en) | 2020-06-14 | 2023-01-19 | Vertex Pharmaceuticals Incorporated | Complement Factor I-related compositions and methods |
| CN114778418B (zh) * | 2022-06-17 | 2022-09-27 | 深圳安侣医学科技有限公司 | 基于显微放大数字图像的血红蛋白分析方法及系统 |
| CN117624347A (zh) * | 2022-08-30 | 2024-03-01 | 天辰生物医药(苏州)有限公司 | 抗人补体c5抗体以及其融合蛋白 |
| EP4617287A1 (en) * | 2022-11-10 | 2025-09-17 | Longbio Pharma (Suzhou) Co., Ltd. | Complement-inhibitory hybrid protein mutant and antibody fusion protein thereof |
| CN118373913B (zh) * | 2024-05-08 | 2024-11-01 | 上海百英生物科技股份有限公司 | 一种抗人Tim-3单克隆抗体及其制备方法 |
| CN118878672A (zh) * | 2024-08-01 | 2024-11-01 | 河北康立德生物科技有限公司 | 一种抗曲霉半乳甘露聚糖单克隆抗体、试剂盒及其应用 |
| CN119638823A (zh) * | 2024-12-10 | 2025-03-18 | 中国医学科学院病原生物学研究所 | 检测a35r蛋白的单克隆抗体及其应用 |
| CN119431565B (zh) * | 2025-01-10 | 2025-04-08 | 成都迈科康生物科技有限公司 | 一种抗hpv16型e6蛋白和e7蛋白的抗体、检测产品及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| EP1284752A4 (en) * | 2000-04-26 | 2004-08-18 | Elusys Therapeutics Inc | BISPECIFIC MOLECULES AND USES THEREOF |
| US7708999B2 (en) * | 2001-12-28 | 2010-05-04 | Kyowa Hakko Kirin Co., Ltd. | Remedies for arthritis |
| WO2005063815A2 (en) * | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| WO2006042252A2 (en) * | 2004-10-08 | 2006-04-20 | Potentia Pharmeceuticals, Inc. | Viral complement control proteins for eye disorders |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US9815890B2 (en) * | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
| AU2011336702B2 (en) | 2010-11-29 | 2016-10-06 | Novelmed Therapeutics, Inc. | Neoantibodies for diagnosing tissue injury |
| AU2013302441B2 (en) * | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
| AU2014209350B8 (en) * | 2013-01-23 | 2019-04-18 | Department Of Veterans Affairs (Us) | Targeting constructs based on natural antibodies and uses thereof |
| AU2014348683B2 (en) * | 2013-11-18 | 2020-11-05 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| US10035848B2 (en) | 2014-01-08 | 2018-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody targeting cell surface deposited complement protein C3d and use thereof |
| ES2865825T3 (es) * | 2014-04-01 | 2021-10-18 | Rubius Therapeutics Inc | Procedimientos y composiciones para inmunomodulación |
| CN106687123A (zh) * | 2014-06-05 | 2017-05-17 | 科罗拉多州大学评议会 | Map44多肽和基于天然抗体的构建体及其用途 |
| CR20170383A (es) * | 2015-01-23 | 2017-11-22 | Sanofi Sa | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 |
-
2019
- 2019-12-11 MX MX2021006930A patent/MX2021006930A/es unknown
- 2019-12-11 KR KR1020217021586A patent/KR102762828B1/ko active Active
- 2019-12-11 SG SG11202106073QA patent/SG11202106073QA/en unknown
- 2019-12-11 CN CN201980091627.3A patent/CN113660944A/zh active Pending
- 2019-12-11 PH PH1/2021/551398A patent/PH12021551398A1/en unknown
- 2019-12-11 MY MYPI2021003245A patent/MY209796A/en unknown
- 2019-12-11 MA MA054468A patent/MA54468A/fr unknown
- 2019-12-11 AU AU2019398214A patent/AU2019398214C1/en active Active
- 2019-12-11 EP EP19895581.7A patent/EP3893916A4/en active Pending
- 2019-12-11 WO PCT/US2019/065741 patent/WO2020123662A2/en not_active Ceased
- 2019-12-11 KR KR1020257003118A patent/KR20250021629A/ko active Pending
- 2019-12-11 JP JP2021533356A patent/JP7444886B2/ja active Active
-
2021
- 2021-06-09 IL IL283841A patent/IL283841A/en unknown
-
2023
- 2023-12-15 US US18/542,100 patent/US20240301043A1/en active Pending
-
2024
- 2024-02-21 AU AU2024201109A patent/AU2024201109A1/en active Pending
- 2024-02-22 JP JP2024025175A patent/JP7811315B2/ja active Active
-
2025
- 2025-12-24 JP JP2025279839A patent/JP2026053563A/ja active Pending